Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study)

Active, not recruitingOBSERVATIONAL
Enrollment

2,000

Participants

Timeline

Start Date

April 21, 2024

Primary Completion Date

September 30, 2028

Study Completion Date

December 31, 2031

Conditions
Atrial Fibrillation (AF)
Trial Locations (1)

02841

Korea University Anam Hospital, Seoul

All Listed Sponsors
collaborator

Korea University Ansan Hospital

OTHER

collaborator

Mediplex Sejong Hospital

UNKNOWN

collaborator

Chungnam National University Hospital

OTHER

collaborator

Chonnam National University Hospital

OTHER

collaborator

Kyung Hee University Hospital at Gangdong

OTHER

collaborator

Kyungpook National University Hospital

OTHER

collaborator

Korea University Guro Hospital

OTHER

collaborator

InjeUniversityIlsanPaikHospital

UNKNOWN

collaborator

Wonkwang University Hospital

OTHER

collaborator

Keimyung University Dongsan Medical Center

OTHER

lead

Korea University Anam Hospital

OTHER

NCT06779695 - Prediction of Systemic Thromboembolism and Bleeding in Atrial Fibrillation Patients With Factor Xa Inhibitor (Apixaban, Rivaroxaban) by Echocardiographic Parameters: Prospective Observational Study (AF-ECHO Study) | Biotech Hunter | Biotech Hunter